Kobayashi Pharmaceutical Co., Ltd. (TYO:4967)
Japan
· Delayed Price · Currency is JPY 5,632.00
+18.00 (0.32%)
At close: Mar 9, 2026
Kobayashi Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Revenue | 165,742 | 165,600 | 173,455 | 166,258 | 155,252 | Upgrade
|
| Revenue Growth (YoY) | 0.09% | -4.53% | 4.33% | 7.09% | 3.15% | Upgrade
|
| Cost of Revenue | 81,030 | 77,997 | 77,079 | 73,927 | 66,478 | Upgrade
|
| Gross Profit | 84,712 | 87,603 | 96,376 | 92,331 | 88,774 | Upgrade
|
| Selling, General & Admin | 54,126 | 48,040 | 57,457 | 53,902 | 52,072 | Upgrade
|
| Research & Development | 9,122 | 9,109 | 9,004 | 8,327 | 7,522 | Upgrade
|
| Amortization of Goodwill & Intangibles | 1,390 | 1,407 | 1,128 | 998 | 862 | Upgrade
|
| Other Operating Expenses | 1,264 | 753 | 930 | 767 | 718 | Upgrade
|
| Operating Expenses | 69,867 | 62,893 | 70,749 | 65,825 | 62,823 | Upgrade
|
| Operating Income | 14,845 | 24,710 | 25,627 | 26,506 | 25,951 | Upgrade
|
| Interest Expense | -28 | -28 | -29 | -18 | -18 | Upgrade
|
| Interest & Investment Income | 999 | 815 | 762 | 578 | 588 | Upgrade
|
| Currency Exchange Gain (Loss) | 278 | 330 | 40 | 231 | 481 | Upgrade
|
| Other Non Operating Income (Expenses) | 900 | 1,033 | 930 | 983 | 1,011 | Upgrade
|
| EBT Excluding Unusual Items | 16,994 | 26,860 | 27,330 | 28,280 | 28,013 | Upgrade
|
| Gain (Loss) on Sale of Investments | 3,041 | 635 | 436 | -89 | 84 | Upgrade
|
| Gain (Loss) on Sale of Assets | 2,119 | -51 | -59 | -52 | -70 | Upgrade
|
| Asset Writedown | -14,775 | - | -59 | -69 | -309 | Upgrade
|
| Other Unusual Items | -3,636 | -13,531 | -89 | -121 | -83 | Upgrade
|
| Pretax Income | 3,743 | 13,913 | 27,559 | 27,949 | 27,635 | Upgrade
|
| Income Tax Expense | 83 | 3,842 | 7,221 | 7,927 | 7,920 | Upgrade
|
| Earnings From Continuing Operations | 3,660 | 10,071 | 20,338 | 20,022 | 19,715 | Upgrade
|
| Minority Interest in Earnings | -4 | -4 | - | - | - | Upgrade
|
| Net Income | 3,656 | 10,067 | 20,338 | 20,022 | 19,715 | Upgrade
|
| Net Income to Common | 3,656 | 10,067 | 20,338 | 20,022 | 19,715 | Upgrade
|
| Net Income Growth | -63.68% | -50.50% | 1.58% | 1.56% | 2.66% | Upgrade
|
| Shares Outstanding (Basic) | 74 | 74 | 76 | 77 | 78 | Upgrade
|
| Shares Outstanding (Diluted) | 74 | 74 | 76 | 77 | 78 | Upgrade
|
| Shares Change (YoY) | 0.00% | -1.98% | -1.67% | -1.27% | -0.05% | Upgrade
|
| EPS (Basic) | 49.18 | 135.42 | 268.16 | 259.61 | 252.35 | Upgrade
|
| EPS (Diluted) | 49.18 | 135.42 | 268.16 | 259.59 | 252.35 | Upgrade
|
| EPS Growth | -63.68% | -49.50% | 3.30% | 2.87% | 2.71% | Upgrade
|
| Free Cash Flow | 12,337 | -14,810 | 5,604 | 17,167 | 18,756 | Upgrade
|
| Free Cash Flow Per Share | 165.96 | -199.22 | 73.89 | 222.57 | 240.08 | Upgrade
|
| Dividend Per Share | - | 102.000 | 101.000 | 90.000 | 83.000 | Upgrade
|
| Dividend Growth | - | 0.99% | 12.22% | 8.43% | 7.79% | Upgrade
|
| Gross Margin | 51.11% | 52.90% | 55.56% | 55.54% | 57.18% | Upgrade
|
| Operating Margin | 8.96% | 14.92% | 14.77% | 15.94% | 16.71% | Upgrade
|
| Profit Margin | 2.21% | 6.08% | 11.72% | 12.04% | 12.70% | Upgrade
|
| Free Cash Flow Margin | 7.44% | -8.94% | 3.23% | 10.33% | 12.08% | Upgrade
|
| EBITDA | 23,590 | 32,732 | 31,684 | 31,864 | 30,786 | Upgrade
|
| EBITDA Margin | 14.23% | 19.77% | 18.27% | 19.16% | 19.83% | Upgrade
|
| D&A For EBITDA | 8,745 | 8,022 | 6,057 | 5,358 | 4,835 | Upgrade
|
| EBIT | 14,845 | 24,710 | 25,627 | 26,506 | 25,951 | Upgrade
|
| EBIT Margin | 8.96% | 14.92% | 14.77% | 15.94% | 16.71% | Upgrade
|
| Effective Tax Rate | 2.22% | 27.61% | 26.20% | 28.36% | 28.66% | Upgrade
|
| Advertising Expenses | 16,862 | 11,575 | 23,038 | 22,389 | 22,499 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.